

Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors

Supplemental Table 2. Dose Exposure

	Cohort A1^a (3 mg) N = 3	Cohort A2 (10 mg) N = 3	Cohort A3^a (30 mg) N = 3	Cohort A4^b (70 mg) N = 3
Cycles received, n				
Median (IQR)	2 (2-6)	4 (2-5)	4 (2-4)	1 (1-2)
Duration of therapy, days				
Median (IQR)	56 (42-168)	100 (56-126)	98 (57-98)	28 (14-42)
Cumulative dose, mg				
Median (IQR)	12 (9-36)	70 (40-90)	210 (120-210)	140 (70-210)

Abbreviation: IQR, interquartile range.

^a 1 patient in this cohort discontinued treatment due to study termination by sponsor decision.

^b 3 patients in this cohort discontinued treatment due to study termination by sponsor decision.